The Proteomics Unit of the Josep Carreras Leukaemia Research Institute, part of the Carlos III Health Institute (ISCIII) and the Proteomics Network ProteoRed, offers mass spectrometry services to the academic and to the private sector under request.
The unit’s main activity is to promote the incorporation of proteomics as a key tool for the development of clinical and basic projects at our institution. Our main work consists of offering innovative, high-quality proteomic and peptidomic services that allow the best therapeutic and human health solutions to be selected.
How do we support you?
- By providing scientific and technological support to high-level research projects in the field of proteomics according to international standard procedures.
- By providing researchers with scientific advice, from the project’s planning and experimental design stage to the execution phase, processing of samples and interpretation of results, and support during presentations and writing of results for publication.
- Through dissemination and training for researchers on the methodology and applications of the techniques offered.
- By contributing to the promotion of innovation in health technologies and the transfer of the knowledge generated to the public health service, and supporting genetic, epigenetic and pharmacogenetic diagnosis.
Proteomic analysis is a very powerful approach to addressing key challenges in clinical and health research. This approach can be used for different aspects of clinical and health sciences, such as biomarker discovery, drug target identification and food technology.
Biomarker discovery from a wide range of samples to improve precision medicine at different levels: a) early diagnostic, and b) prognosis to predict disease progression and guide treatment selection.